Evidence for GLP-1 receptor agonists: A systematic review and meta-analysis (eight studies, n=27639) in individuals with T2D and ESRD, by Krisanapan et al. [96], reported that GLP-1 receptor agonists decreased eGFR from −0.6 to −0.1 mL/minute/1.73 m2/month and had a good safety profile. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.